Published in PLoS One on October 16, 2015
Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes. Ann Oncol (2015) 1.48
Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol (2017) 0.94
Cons: Can liquid biopsy replace tissue biopsy?-the US experience. Transl Lung Cancer Res (2016) 0.93
Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer (2017) 0.88
Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov (2016) 0.86
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discov (2016) 0.85
Cell-free circulating tumor DNA in cancer. Chin J Cancer (2016) 0.85
Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Oncotarget (2016) 0.81
Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations. Genome Med (2016) 0.79
Liquid Biopsies for Cancer: Coming to a Patient near You. J Clin Med (2017) 0.78
MET amplification in metastatic colorectal cancer: An acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget (2016) 0.78
Targeted Cancer Therapy: Vital Oncogenes and a New Molecular Genetic Paradigm for Cancer Initiation Progression and Treatment. Int J Mol Sci (2016) 0.77
Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients. Mol Oncol (2015) 0.77
Tumor Evolution: Linear, Branching, Neutral or Punctuated? Biochim Biophys Acta (2017) 0.77
Clinical applications of liquid biopsies in gastrointestinal oncology. J Gastrointest Oncol (2016) 0.76
The Pursuit of Noninvasive Diagnosis of Lung Cancer. Semin Respir Crit Care Med (2016) 0.75
Technological considerations for genome-guided diagnosis and management of cancer. Genome Med (2016) 0.75
Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery. Sci Rep (2017) 0.75
Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution. Sci Rep (2017) 0.75
Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. J Hematol Oncol (2017) 0.75
Circulating tumor DNA in hepatocellular carcinoma: trends and challenges. Cell Biosci (2016) 0.75
Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient Management. Int J Mol Sci (2017) 0.75
Liquid biopsy genotyping in lung cancer: ready for clinical utility? Oncotarget (2017) 0.75
Current status of research and treatment for non-small cell lung cancer in never-smoking females. Cancer Biol Ther (2017) 0.75
Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature. Oncotarget (2017) 0.75
Modular probes for enriching and detecting complex nucleic acid sequences. Nat Chem (2017) 0.75
Genomic alterations in circulating tumor DNA from diverse cancer patients identified by next-generation sequencing. Cancer Res (2017) 0.75
Clinical utility of circulating cell-free DNA in advanced colorectal cancer. PLoS One (2017) 0.75
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
Accurate whole human genome sequencing using reversible terminator chemistry. Nature (2008) 90.20
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med (2012) 44.56
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
The clonal evolution of tumor cell populations. Science (1976) 24.39
Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature (1980) 17.69
Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med (2013) 11.93
Diagnostic tests. 1: Sensitivity and specificity. BMJ (1994) 11.35
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer (2011) 7.69
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet (1998) 6.88
Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol (2010) 6.34
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA (2014) 6.32
The causes and consequences of genetic heterogeneity in cancer evolution. Nature (2013) 5.91
The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group. Genet Med (2009) 5.69
Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med (2012) 5.69
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science (2014) 5.63
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med (2014) 4.98
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
Circulating nucleic acids (CNAs) and cancer--a survey. Biochim Biophys Acta (2006) 4.60
Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 4.39
BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods (2006) 4.21
Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol (2014) 3.70
Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat Biotechnol (2012) 3.62
Improved confidence intervals for the difference between binomial proportions based on paired data. Stat Med (1998) 3.57
Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol (2011) 3.46
Intratumor heterogeneity: evolution through space and time. Cancer Res (2012) 3.45
[Not Available]. C R Seances Soc Biol Fil (1948) 3.32
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res (2012) 3.14
Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer (1998) 3.12
Tumor clone dynamics in lethal prostate cancer. Sci Transl Med (2014) 2.93
The implications of clonal genome evolution for cancer medicine. N Engl J Med (2013) 2.78
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol (2014) 2.73
Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol (2012) 2.43
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society: international multidisciplinary classification of lung adenocarcinoma: executive summary. Proc Am Thorac Soc (2011) 2.39
Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol (2011) 2.29
NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw (2011) 2.24
Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol (2014) 2.23
Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Clin Cancer Res (2015) 2.12
Molecular tumor board: the University of California-San Diego Moores Cancer Center experience. Oncologist (2014) 2.09
KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene (2006) 2.07
Clinical next-generation sequencing in patients with non-small cell lung cancer. Cancer (2014) 1.76
Breast cancer version 3.2014. J Natl Compr Canc Netw (2014) 1.63
Validation of biomarker-based risk prediction models. Clin Cancer Res (2008) 1.57
Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov (2014) 1.55
MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer (2009) 1.48
Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med (2012) 1.45
Trends in use and safety of image-guided transthoracic needle biopsies in patients with cancer. J Oncol Pract (2015) 1.45
Ultrasound-guided liver biopsy for parenchymal liver disease: an economic analysis. Dig Dis Sci (1998) 1.41
Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol (1987) 1.37
EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol (2007) 1.25
Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin Cancer Res (2014) 1.22
The search for ESR1 mutations in breast cancer. Nat Genet (2013) 1.13
New insights into the mechanisms of organ-specific breast cancer metastasis. Semin Cancer Biol (2012) 1.10
Toward complete and accurate reporting of studies of diagnostic accuracy. The STARD initiative. Am J Clin Pathol (2003) 1.10
A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR. Clin Biochem (2013) 1.09
Melanoma, version 4.2014. J Natl Compr Canc Netw (2014) 1.07
Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma. Int J Cancer (2013) 1.03
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. Cancer Treat Rev (2014) 1.01
Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov (2015) 1.01
Realizing the potential of plasma genotyping in an age of genotype-directed therapies. J Natl Cancer Inst (2014) 0.95
Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients. Ann Oncol (2011) 0.89
High-resolution characterization of sequence signatures due to non-random cleavage of cell-free DNA. BMC Med Genomics (2015) 0.87
Surveillance computed tomography after complete resection for non-small cell lung cancer: results and costs. J Thorac Cardiovasc Surg (2005) 0.86
NCCN Working Group report: designing clinical trials in the era of multiple biomarkers and targeted therapies. J Natl Compr Canc Netw (2014) 0.86
Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. Int J Cancer (2014) 0.86
A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clin Cancer Res (2015) 0.83
Cancer. Attack of the clones. Science (2014) 0.81
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med (2015) 1.93
Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer (2013) 1.43
High-throughput sequencing and copy number variation detection using formalin fixed embedded tissue in metastatic gastric cancer. PLoS One (2014) 0.97
Integrated genomic analyses identify frequent gene fusion events and VHL inactivation in gastrointestinal stromal tumors. Oncotarget (2016) 0.81
Aberrant CDK4 amplification in refractory rhabdomyosarcoma as identified by genomic profiling. Sci Rep (2014) 0.80
Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. Oncotarget (2017) 0.79
Exome sequencing identifies early gastric carcinoma as an early stage of advanced gastric cancer. PLoS One (2013) 0.79
Molecular characterization of colorectal cancer patients and concomitant patient-derived tumor cell establishment. Oncotarget (2016) 0.77
Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. Cancer Discov (2017) 0.75
Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center's experiences. Oncotarget (2017) 0.75
Bridging genomics and phenomics of gastric carcinoma. Int J Cancer (2019) 0.75
Correlation between MEK signature and Ras gene alteration in advanced gastric cancer. Oncotarget (2017) 0.75